- Home
- YMAT vs CANF Comparison
YMAT vs CANF Comparison
Compare YMAT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YMAT | CANF |
|---|---|---|
| Founded | 1970 | 1994 |
| Country | Taiwan | Israel |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 6.2M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | YMAT | CANF |
|---|---|---|
| Price | $0.37 | $4.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | ★ 3.6M | 619.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $461.72 |
| Revenue Next Year | N/A | $290,391.28 |
| P/E Ratio | $10.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.17 |
| 52 Week High | $6.45 | $10.40 |
Technical Indicators
Market Signals| Indicator | YMAT | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 41.31 | 51.99 |
| Support Level | N/A | $3.93 |
| Resistance Level | $0.68 | $4.74 |
| Average True Range (ATR) | 0.08 | 0.71 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 14.50 | 6.13 |
Price Performance
Historical ComparisonAbout YMAT J-Star Holding Co. Ltd. Ordinary Shares
J Star Holding Co Ltd is engaged in the research, development and manufacturing of carbon fiber for a wide variety of products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.